Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study

Jahr

2017

Autoren

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

Verlag

BMC Neurol. 2017 Jan 18;17(1):11.

Link

https://doi.org/10.1186/s12883-016-0789-7

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning